Available and affordable complementary treatments for COVID‐19: From hypothesis to pilot studies and the need for implementation - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Clinical and Translational Allergy Année : 2022

Available and affordable complementary treatments for COVID‐19: From hypothesis to pilot studies and the need for implementation

Résumé

Vaccination is a highly effective preventive measure against COVID‐19. However, complementary treatments are needed to better control the disease. Fermented vegetables and spices, agonists of the antioxidant transcription factor nuclear factor (erythroid‐derived 2)‐like 2 (Nrf2) and TRPA1/V1 channels (Transient Receptor Potential Ankyrin 1 and Vanillin 1), may help in the control of COVID‐19. Some preliminary clinical trials suggest that curcumin (spice) can prevent some of the COVID‐19 symptoms. Before any conclusion can be drawn and these treatments recommended for COVID‐19, the data warrant confirmation. In particular, the benefits of the foods need to be assessed in more patients, through research studies and large trials employing a double‐blind, placebo‐controlled design.
Fichier principal
Vignette du fichier
CLT2-12-e12127.pdf (489.32 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Licence : CC BY - Paternité

Dates et versions

hal-04538702 , version 1 (09-04-2024)

Licence

Paternité

Identifiants

Citer

Jean Bousquet, Tari Haahtela, Hubert Blain, Wienczyslawa Czarlewski, Torsten Zuberbier, et al.. Available and affordable complementary treatments for COVID‐19: From hypothesis to pilot studies and the need for implementation. Clinical and Translational Allergy, 2022, 12 (3), pp.e12127. ⟨10.1002/clt2.12127⟩. ⟨hal-04538702⟩
1 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More